May 02, 2016 4:39 AM ET


Company Overview of Sandoz International GmbH

Company Overview

Sandoz International GmbH develops, manufactures, and markets generic pharmaceutical products. It offers biosimilar, oncology injectable, respiratory, anti-infective, and biotechnological products, as well as medicines for various therapeutic areas, such as cardiovascular systems, central nervous systems, alimentary tracts and metabolisms, antineoplastic and immunomodulation agents, respiratory systems, and blood and blood forming organs. The company also offers drugs for suppressing recurrence of ischemic cerebrovascular disorder, lowering cholesterol, and preventing organ transplant rejection (kidney, liver, heart, lung, pancreas, and small intestine). It serves customers in Germany and in...

Industriestrasse 25

Holzkirchen,  83607



49 8024 476 0


49 8024 476 2599

Key Executives for Sandoz International GmbH

Global Head
Age: 41
Chief Financial Officer
Head of North American Operations and President of Sandoz US
Head of Legal and General Counsel
Head of Central & Eastern Europe, Middle East and Africa
Compensation as of Fiscal Year 2015.

Sandoz International GmbH Key Developments

Sandoz Licenses its Biosimilar Rituximab to Kyowa Hakko Kirin Co., Ltd in Japan

Sandoz announced that it has entered into an exclusive license agreement with Kyowa Hakko Kirin Co., Ltd. for the distribution and promotion of its biosimilar rituximab - a monoclonal antibody, in Japan. Under the terms of the agreement, Sandoz will file for marketing authorization of biosimilar rituximab and its manufacture if approved. Kyowa Hakko Kirin will be responsible for all sales, marketing and promotion activities in Japan. Kyowa Hakko Kirin will pay Sandoz an up-front fee, subsequent payments for regulatory filing, regulatory approval, success-based milestones, royalties as well as defined supply price for every order.

Sandoz International GmbH Presents at BIO-Europe 2015, Nov-02-2015

Sandoz International GmbH Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.

Sandoz Launches ZarxioTM (Filgrastim-Sndz), the First Biosimilar in the United States

Sandoz International GmbH announced that Zarxio(TM) (filgrastim-sndz) is now available in the United States. Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA) and the first to launch in the US. Sandoz understands the importance of providing comprehensive patient support services in the oncology setting. With the launch of Zarxio, Sandoz is also proud to offer Sandoz One SourceTM a patient services center, providing support that connects the patient to the information and resources they need. The launch follows the FDA approval of Zarxio on March 6, 2015. The approval, via the new biosimilars pathway established under the Biologics Price Competition and Innovation Act, was based on a comprehensive package of analytical, nonclinical, and clinical data, which confirmed that Zarxio is highly similar with no clinically meaningful differences to the US-licensed reference product. The successful Sandoz pivotal head-to-head PIONEER study was the final piece of data contributing to the totality of evidence used by FDA to approve Zarxio as biosimilar to the reference product. Importantly, the data demonstrating high similarity was sufficient to allow extrapolation of use of Zarxio to five indications of the reference product.

Similar Private Companies By Industry

Company Name Region
IMTM GmbH Europe
Dr. R. Pfleger GmbH Europe
ALRISE Biosystems GmbH Europe
Myr Europe
PGD Profusio Greven GesundHeits GmbH Deutschland Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sandoz International GmbH, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at